Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 7Neoplasms 6Adenocarcinoma 1

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × abemaciclib × Tumor-Agnostic × Clear all
NCT03997448 2024-02-20

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Big Ten Cancer Research Consortium

Phase 2 Terminated
3 enrolled 10 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡